| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.057 | 0.07 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.07 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.091 | 0.07 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.086 | 0.07 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.058 | 0.07 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.054 | 0.07 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.07 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.096 | 0.07 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.08 |